Cargando…

Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial Cancer

Because epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and promotion of tumorigenesis in endometrial cancers, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. In this review, we discu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takai, Noriyuki, Narahara, Hisashi
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2010
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821626/ https://www.ncbi.nlm.nih.gov/pubmed/20169171 http://dx.doi.org/10.1155/2010/923824

Ejemplares similares

Histone Deacetylase Inhibitor Therapy in Epithelial Ovarian Cancer
por: Takai, Noriyuki, et al.
Publicado: (2010)

Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
por: Psilopatis, Iason, et al.
Publicado: (2021)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
por: Hassell, Kelly N.
Publicado: (2019)

Epigenetic Therapy in Human Choriocarcinoma
por: Takai, Noriyuki, et al.
Publicado: (2010)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Association of histone deacetylase expression with histology and prognosis of ovarian cancer
por: Yano, Mitsutake, et al.
Publicado: (2018)

Potential use of histone deacetylase inhibitors in cancer therapy
por: Gołąbek, Karolina, et al.
Publicado: (2015)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells
por: Wawruszak, Anna, et al.
Publicado: (2019)

Array-Based Approaches for the Identification of Epigenetic Silenced Tumor Suppressor Genes
por: Takai, Noriyuki, et al.
Publicado: (2008)

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
por: Bishton, Mark J., et al.
Publicado: (2010)

Interpreting clinical assays for histone deacetylase inhibitors
por: Martinet, Nadine, et al.
Publicado: (2011)

Dual Inhibitors Against Topoisomerases and Histone Deacetylases
por: Seo, Young Ho
Publicado: (2015)

Histone Deacetylase Inhibitors and Diabetic Kidney Disease
por: Hadden, Mitchell J., et al.
Publicado: (2018)

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
por: Verza, Flávia Alves, et al.
Publicado: (2020)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022)

Histone Deacetylase Inhibitors from Marine Invertebrates
por: Luparello, Claudio, et al.
Publicado: (2020)

The Impact of Fluorination on the Design of Histone Deacetylase Inhibitors
por: Tien Anh, Duong, et al.
Publicado: (2023)

Histone deacetylase 1 facilitates aerobic glycolysis and growth of endometrial cancer
por: Wu, Qiongwei, et al.
Publicado: (2021)

The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy
por: Psilopatis, Iason, et al.
Publicado: (2023)

Regulation of Immune Responses by Histone Deacetylase Inhibitors
por: Licciardi, Paul V., et al.
Publicado: (2012)

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?
por: Stintzing, Sebastian, et al.
Publicado: (2011)

Zinc binding groups for histone deacetylase inhibitors
por: Zhang, Lei, et al.
Publicado: (2018)

Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
por: Tandon, Nidhi, et al.
Publicado: (2016)

Tumorigenic Effects of Tamoxifen on the Female Genital Tract
por: Nasu, Kaei, et al.
Publicado: (2008)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Changes in the Expression of TBP-2 in Response to Histone Deacetylase Inhibitor Treatment in Human Endometrial Cells
por: Kim, Hye In, et al.
Publicado: (2021)

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
por: Xu, Qing-Yu, et al.
Publicado: (2020)

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
por: Li, Guo, et al.
Publicado: (2020)

Preclinical Efficacy and Toxicity Analysis of the Pan-Histone Deacetylase Inhibitor Gossypol for the Therapy of Colorectal Cancer or Hepatocellular Carcinoma
por: Mayer, Mascha, et al.
Publicado: (2022)

Histone deacetylase inhibitors: clinical implications for hematological malignancies
por: Tambaro, Francesco Paolo, et al.
Publicado: (2010)

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis, Katherine, et al.
Publicado: (2013)

Histone Deacetylases and Their Isoform-Specific Inhibitors in Ischemic Stroke
por: Demyanenko, Svetlana, et al.
Publicado: (2021)

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
por: Tan, Jiahuai, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_5g0rkpg92nvjbqvjgf58k5ohcl